Uveitis - Epidemiology Forecast - 2034

Uveitis - Epidemiology Forecast - 2034

DelveInsight’s ‘Uveitis – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of uveitis, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Uveitis Understanding

Uveitis is a rare condition in which all or part of the uvea (middle layer of the eye wall) becomes inflamed. The uvea includes the choroid, the ciliary body, and the iris. Uveitis encompasses a diverse group of inflammatory ocular diseases and may also affect the lens, retina, optic nerve, and vitreous humor (the gel-like fluid inside the eye). It may be caused by an injury, infection, a tumor in the eye, or an autoimmune or inflammatory condition. One or both eyes may be affected.

The signs and symptoms include redness and pain in the eye, sensitivity to light, blurred vision, dark floating spots in the vision, and vision loss. Additionally, the symptoms may occur suddenly and get worse quickly. If not treated, uveitis can lead to tissue scarring and blindness. It is broadly classified as infectious and noninfectious. Infectious uveitis can result from bacteria or viruses in the eye, while noninfectious uveitis (NIU) can occur with systemic autoimmune disease and autoimmune diseases localized to the eye. NIU represents the majority of uveitis cases. Based on the anatomical location of inflammation in the eye, uveitis is categorized as anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis.

Uveitis Diagnosis

A thorough eye exam is needed to diagnose uveitis. The clinical diagnosis is often based on spillover inflammation (i.e., cells and protein flare) observed with a slit lamp in the aqueous or vitreous humor. Further, blood tests and X-rays may be used to determine whether another underlying systemic disorder is causing the condition.

Continued in the report…..

Uveitis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of uveitis, type-specific diagnosed prevalent cases of uveitis, diagnosed prevalent cases of uveitis by anatomical location, etiology-specific diagnosed prevalent cases of uveitis, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Uveitis Detailed Epidemiology Segmentation

According to DelveInsight’s estimates, the total diagnosed prevalent cases of uveitis in the 7MM were approximately 1,009,025 in 2022, which is expected to increase by 2034.

Among the 7MM, the US accounted for approximately 37.49%, EU4 and the UK for nearly 41.21%, and Japan for around 21.30% of the total diagnosed prevalent cases of uveitis in 2022; these cases are expected to change by 2034.

Among EU4 and the UK, in 2022 France accounted for the highest diagnosed prevalent population of uveitis, with nearly 88,521 cases, followed by the UK with approximately 88,129 cases. On the other hand, Spain had the lowest diagnosed prevalent population with nearly 75,461 cases in 2022. These cases are expected to change during the study period.

The diagnosed prevalence of uveitis is divided into two subtypes: infectious uveitis and NIU. As per the assessment by DelveInsight’s analysts, in 2022, in the US, there were nearly 33,695 cases of infectious and 344,587 cases of NIU.

Based on its anatomical location, uveitis is divided into four types: anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis. In EU4 and the UK, anterior uveitis accounted for the highest cases, with approximately 203,439 diagnosed prevalent cases of uveitis, followed by nearly 84,154 cases of posterior uveitis, around 81,773 cases of pan uveitis, and 46,485 cases of intermediate uveitis in 2022.

As per DelveInsight’s analysis, Japan accounted for approximately 214,892 cases, out of which nearly 8,039 cases of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behçet’s disease, 8,658 Vogt–Koyanagi–Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others based on etiology-specific diagnosed prevalent cases in 2022. The uveitis cases are expected to change during the forecast period.

Scope of the Report

The report covers a descriptive overview of uveitis, explaining its symptoms, pathophysiology, and various diagnostic approaches.

The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.

The report assesses the disease risk and burden of uveitis.

The report helps recognize the growth opportunities in the 7MM concerning the patient population.

The report provides the segmentation of the disease epidemiology for the 7MM, by total diagnosed prevalent of uveitis, type-specific diagnosed prevalent cases of uveitis, diagnosed prevalent cases of uveitis by anatomical location, and etiology-specific diagnosed prevalent cases of uveitis.

Report Highlights

12 years Forecast of Uveitis

The 7MM Coverage

Total Diagnosed Prevalent Cases of Uveitis

Type-Specific Diagnosed Prevalent Cases of Uveitis

Diagnosed Prevalent Cases of Uveitis by Anatomical Location

Etiology-Specific Diagnosed Prevalent Cases of Uveitis

Key Questions Answered

What are the disease risks and burdens of uveitis?

What is the historical uveitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?

What would be the forecasted patient pool of uveitis at the 7MM level?

What growth opportunities will be across the 7MM concerning the patient population with uveitis?

Which country would have the highest diagnosed prevalent population of uveitis among the countries mentioned above during the forecast period (2023–2034)?

At what CAGR is the population expected to grow across the 7MM forecast period (2023–2034)?

Reasons to Buy

The uveitis report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the 7MM uveitis epidemiology forecast.

The uveitis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.

The uveitis epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 12-year forecast period using reputable sources.

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of Disease by Segmentation

Factors Driving Growth in a Specific Patient Population

Geographies Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034